SSRI products

CI INSIGHT REPORT™

In-Depth Industry Landscape Analysis for Various Therapeutic Areas in Japan

CI INSIGHT REPORT Highlights:

  • In-depth Analysis of current clinical advancements for pharmaceutical products, leveraging both primary and secondary research methods in Japan
  • Comprehensive Market Insights on the current state and expected evolution of the therapeutic area in Japan, including:
    • Prescription Trends: Current physician practices and emerging developments in drug pipelines
    • Competitor Intelligence: multi-faceted view of both new and existing players

Report Structure:

  • Part 1: Overview of the industry landscape, compiled from publicly available sources.
  • Part 2: Insights from quantitative surveys conducted with Tx specialists.
  • Part 3: In-depth discussions with Key Opinion Leaders (KOLs), focusing on future trends and pipeline evaluations.

Report Delivery Options:

  • Japanese Version (USD 15,000)
  • English Translated Version (additional translation fees apply; please inquire for details)

Report List

No.Theme NameRelease DateSample
1IgA nephropathy NewJanuary 2025
2IBD 2024September 2024PDF
3Psoriasis 2024May 2024PDF
4SSc (systemic scleroderma)January 2024PDF
5NASHSeptember 2023PDF
6LN (lupus nephritis)April 2023PDF
7CKD 2022November 2022
8AD 2022June 2022
9RA 2021November 2021
10Psoriasis 2021June 2021
11SLEJanuary 2021
12IBD 2020September 2020
13AD (atopic dermatitis)March 2020
14CHF (chronic heart failure)November 2019
15PD (Parkinson's disease)July 2019
16RA (rheumatoid arthritis)December 2018
17CKD (chronic kidney disease)August 2018
18PsoriasisJanuary 2018
19Alzheimer's diseaseJuly 2017
20IBD (Crohn's disease/ulcerative colitis)December 2016
scroll top